Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin

Urologic Oncology
Ryan L SteinbergKenneth G Nepple

Abstract

Intravesical Bacillus Calmette-Guérin (BCG) remains the standard of care in the treatment of bladder carcinoma in situ and as adjuvant therapy after thorough transurethral resection of high-grade non-muscle-invasive bladder cancer. Despite BCG therapy, in up to 40% of patients it would recur and 60% to 70% of those would fail repeat BCG induction be deemed BCG unresponsive. For such patients, cystectomy remains the preferred treatment option per the American Urological Association and European Association of Urology, though some patients would be medically unfit or refuse radical surgery. Further intravesical therapy for bladder-preservation therapies may preserve quality of life in these patients and in some cases can be curative. There are numerous non-BCG intravesical salvage options available, including immunotherapy, single-agent chemotherapy, combination chemotherapy, and device-assisted chemotherapy. In addition, investigation of radiation-based treatment and other novel therapies including checkpoint inhibitors (programmed death-1/programmed death ligand-1), are currently underway. In this review, we examine the current status of alternatives to BCG in salvage therapy for bladder preservation.

References

Jan 1, 1987·Cancer Chemotherapy and Pharmacology·H B NiellM Israel
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·C RangelC Cox
Jan 5, 2002·Expert Opinion on Investigational Drugs·M C Filion, N C Phillips
Jun 27, 2002·Current Urology Reports·A M Kamat, D L Lamm
Aug 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido DalbagniDean Bajorin
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Menachem LauferMerrill J Egorin
Apr 11, 2003·The Journal of Urology·Harry W Herr, Guido Dalbagni
Oct 12, 2004·European Urology·Antoine G van der HeijdenJ Alfred Witjes
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alex SparreboomNeil Desai
Jun 14, 2005·International Journal of Urology : Official Journal of the Japanese Urological Association·Chi Wai ChengMiu Ling Li
Mar 7, 2006·The Journal of Urology·Jehonathan H PinthusJohn Trachtenberg
May 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian WeissClaus Rödel
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James M McKiernanMitchell C Benson
Oct 6, 2006·World Journal of Urology·Michael A O'Donnell, Andreas Boehle
Nov 13, 2007·The Journal of Urology·M Craig HallPaul F Schellhammer
Aug 18, 2009·The Journal of Urology·Ofer NativIlan Leibovitch
Mar 24, 2012·Urologic Oncology·M J BaderRaphaela Waidelich
Jul 6, 2013·European Urology·Marko BabjukUNKNOWN European Association of Urology
Oct 24, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Bernhard KissBeat Roth
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

May 10, 2016·Urologic Oncology·Steve Riggs
Apr 1, 2017·Expert Review of Anticancer Therapy·Solomon L WolduYair Lotan
Jul 26, 2017·International Journal of Urology : Official Journal of the Japanese Urological Association·Manmeet Saluja, Peter Gilling
May 8, 2018·Expert Opinion on Emerging Drugs·Jasper Crijnen, Theo M De Reijke
Aug 16, 2019·Expert Opinion on Investigational Drugs·Jennifer TseVitaly Margulis
Mar 10, 2018·Investigative and Clinical Urology·Xuan-Mei PiaoJayoung Kim
Dec 12, 2018·World Journal of Urology·Charles C PeytonPhillippe E Spiess
Apr 13, 2018·European Journal of Nuclear Medicine and Molecular Imaging·Michael E AutenriethAlfred Morgenstern

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis